MLAB Mesa Laboratories, Inc.

Mesa Laboratories, Inc. engages in the design, manufacture, and marketing of instruments and disposable products utilized in healthcare, pharmaceutical, food, and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection, Instruments, Cold Chain Monitoring, and Cold Chain Packaging. The Sterilization and Disinfection segment offers testing services, along with the manufacturing and marketing of biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. The Instrument segment manufactures and markets control instruments and disposable products. The Cold Chain Monitoring segment designs, develops, and markets systems which are used to monitor environmental parameters such as temperature, humidity, and differential pressure. The Cold Chain Packaging segment provides consulting services including compliance monitoring, packaging development, and validation or mapping of transport and storage containers, and thermal packaging products. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.

Company profile

Ticker

MLAB

Exchange

NASDAQ

Website

mesalabs.com

CEO

Gary M. Owens

Incorporated in

Colorado

Location

Colorado

Fiscal year end

Mar 31

Sector

Electronic Technology > Medical Specialties

Industry (SEC)

Industrial Instruments For Measurement, Display, and Control

Danaher • Roper • Fortive • Keysight • Sensata Technologies Holding • MKS Instruments • Cognex • Rudolph • Sypris Solutions • Hurco Cos. ...

SEC CIK

0000724004

Corporate docs

Articles of Incorporation & Bylaws

IRS number

840872291

MLAB stock data

S&P 500

1M 1Y 2Y 5Y

Calendar

1 Jun 20

7 Jul 20

31 Mar 21

News

Company financial data Financial data

Chart MLAB financial data

Quarter (USD)	Mar 20	Dec 19	Sep 19	Jun 19
Revenue	34.21M	31.66M	25.54M	26.29M
Net income	-1.68M	-4.63M	3.06M	4.6M
Diluted EPS	-0.37	-1.06	0.71	1.13
Net profit margin	-4.91%	-14.63%	11.99%	17.49%
Operating income	899K	-3.38M	4.58M	5.39M
Net change in cash	7.4M	-171.46M	238.13M	-2.87M
Cash on hand	81.38M	73.98M	245.44M	7.32M
Cost of revenue	15.57M	16.98M	10.06M	10.15M

Annual (USD)	Mar 20	Mar 19	Mar 18	Mar 17
Revenue	117.69M	103.14M	96.18M	93.67M
Net income	1.35M	7.48M	-2.96M	11.18M
Diluted EPS	0.31	1.86	-0.79	2.91
Net profit margin	1.15%	7.26%	-3.08%	11.94%
Operating income	7.49M	9.78M	2.18M	16.31M
Net change in cash	71.2M	4.72M	-351K	125K
Cash on hand	81.38M	10.19M	5.47M	5.82M
Cost of revenue	52.75M	42.22M	41.56M	40.43M

Financial data from company earnings reports

Recent insider trades

MLAB insider ownership history Insider history

Date	Owner	Security	Transaction	Code	10b5-1	#Shares	#Remaining
15 Jun 20	Kelly David M	Common Stock	Option exercise	Aquire M	No	30	2,810
15 Jun 20	Alltoft Jennifer Sadie	RSU Common Stock	Grant	Aquire A	No	221	221
15 Jun 20	Sullivan John James	Common Stock	Option exercise	Aquire M	No	30	63,731
15 Jun 20	Sullivan John James	RSU Common Stock	Grant	Aquire A	No	310	310
15 Jun 20	Sullivan John James	RSU Common Stock	Option exercise	Dispose M	No	30	90
15 Jun 20	Perez David Brian	RSU Common Stock	Grant	Aquire A	No	221	221
15 Jun 20	Kelly David M	RSU Common Stock	Grant	Aquire A	No	265	265
15 Jun 20	Kelly David M	RSU Common Stock	Option exercise	Dispose M	No	30	90
15 Jun 20	Schmieder John Bradley	Common Stock	Option exercise	Aquire M	No	30	73,467
15 Jun 20	Schmieder John Bradley	RSU Common Stock	Grant	Aquire A	No	265	265

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2020

MLAB institutional ownership history Ownership history

94.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	142	148	-4.1%
Opened positions	12	19	-36.8%
Closed positions	18	13	+38.5%
Increased positions	56	57	-1.8%
Reduced positions	49	48	+2.1%

13F shares	Current	Prev Q	Change
Total value	936.84M	1B	-6.8%
Total shares	4.14M	4.03M	+2.9%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
BLK BlackRock	689.93K	$155.99M	-2.0%
Conestoga Capital Advisors	450.27K	$101.8M	+0.8%
Vanguard	281.23K	$63.58M	-5.1%
Royce & Associates	265.96K	$60.13M	-0.0%
IVZ Invesco	235.26K	$53.19M	+845.7%
N Price T Rowe Associates	216.03K	$48.84M	-9.2%
Ranger Investment Management	174.37K	$39.42M	-1.4%
Kayne Anderson Rudnick Investment Management	161.74K	$36.57M	+1.8%
STT State Street	152.96K	$34.58M	+5.2%
Atlanta Capital Management Co L L C	121.96K	$27.57M	+7.0%

Largest transactions	Shares	Bought/sold	Change
IVZ Invesco	235.26K	+210.38K	+845.7%
Renaissance Technologies	33.9K	-32K	-48.6%
Polar Asset Management Partners	0	-31.59K	EXIT
Eagle Asset Management	28.86K	+28.86K	NEW
THB Asset Management	17.87K	-26.67K	-59.9%
Wasatch Advisors	0	-26.38K	EXIT
Dimensional Fund Advisors	95.81K	-26.06K	-21.4%
WFC Wells Fargo & Company	35.98K	+25.49K	+243.1%
N Price T Rowe Associates	216.03K	-21.79K	-9.2%
AV Aviva	17.5K	+17.5K	NEW

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Thermo Fisher Scientific • STERIS Plc (Ireland) • Amphenol • STERIS Plc (Ireland) • Fortive • STERIS Plc (Ireland)

Management Discussion

Our results of operations and period-over-period change are discussed in the following section. The tables and discussion below should be read in conjunction with the accompanying Consolidated Financial Statements and the notes thereto appearing in Item 8. Financial Statements and Supplementary Data (in thousands, except percent data).

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: academia, academic, adequacy, aggressive, alter, amino, amortizable, antidilutive, Arizona, attrition, bear, bearing, begun, bifurcating, BioaffyTM, biopharmaceutical, Biophrmaceutical, bioprocessing, Biotage, biotech, biotherapeutic, broadly, buying, capturing, catch, CDs, CEM, China, cleared, clinic, clinical, commerce, comparison, composed, confidence, confirm, convert, converted, convertible, converting, correct, debarment, decade, deficiency, demonstrate, denominated, deny, deployed, deposit, diligence, diplomatic, disbarment, disclaim, discovery, disease, disgorgement, dissolved, dissolving, distancing, documentation, downstream, EMA, emerge, emergency, entrance, escalated, exceptionally, exclusion, exempt, expansionary, explicitly, extinguishment, fallen, fell, fight, fighting, foregoing, found, freezing, GPT, grace, Gyrolab, hand, headquartered, home, immunoassay, implicit, implicitly, increasingly, indenture, influenced, inhibited, injured, inorganic, inorganically, instance, ITGC, Japan, kidney, Krona, lacking, landscape, Leasehold, led, legacy, lifted, light, likelihood, loaded, logical, MDR, Meso, Mettler, microfluidic, miniaturizing, mitigate, mitigating, mitigation, myriad, nanoliter, necessarily, newly, NM, Noncompliance, nonlease, nonmonetary, nonoperating, nonrecurring, nonvested, notable, occurrence, operationally, outbreak, outright, overly, par, partway, peptide, precipitated, premarket, premium, proceeding, progressed, promulgated, protein, PSU, PurePep, pursuit, quantification, quantify, readily, recall, recast, recruiting, redemption, reevaluate, refinancing, refusal, remeasured, remotely, renew, renewal, rent, reorganization, reorganized, repay, Repligen, rest, reused, Rexxip, roadmap, ROU, scope, seemingly, segregation, semi, sensing, slightly, slowdown, slowly, smallest, society, Sonata, sought, split, spread, spreading, stay, straight, strain, strictly, strike, Swedish, Symphony, synthesized, temporarily, therapy, tie, TM, Toledo, top, training, travel, travelling, trued, Tucson, unallocated, unamortized, underwriting, Union, unpaid, unqualified, unrelated, Uppsala, upstream, visit, wage, washed, wired, workforce, wrote, xPand, xPloreTM, XT

Removed: ABR, Abrupt, accordion, advertising, Africa, alternate, ambiguity, annualized, ARCA, armed, attack, attestation, Australia, Autoclave, bank, banking, Biopharma, Biothermal, Campbell, Canadian, commercialize, conflict, Cryopak, David, dedicate, dependence, disadvantage, disclose, EBIDTA, energy, ERP, essentially, Euro, exposing, factual, family, fee, flat, forced, French, furnished, Gary, gel, gradually, HANSAmed, hereunder, hired, Holiday, incubation, insulation, internet, introducing, IRS, JPMorgan, Letter, LIBOR, mail, Markham, Michael, minimize, moving, Mydent, Omaha, Ontario, overnight, Pelican, phase, philosophy, physician, powering, prime, problematic, professional, promoted, provisional, publicly, Pulse, qualified, Rapid, ratio, real, Registration, relocate, relocation, representative, Rudolph, run, salary, secured, separation, Sonoco, South, subjectivity, supplying, syndicate, TempTrust, thermal, Thermosafe, transition, Traverse, treated, unclear, unused, unvested, Vice, weather

From filing 10-K 2020 FY